What is the life expectancy of people with multiple myeloma and lcdd?

Depends on heart: The light chain deposition disease is unlikely to affect survival. In fact a review of myeloma and kidney failure published last year demonstrated no change in outcome in myeloma patients with or without kidney failure. The biggest predictor of outcome is response to chemotherapy. Velcade (bortezomib) (new chemo) has been a game changer. In addition, patients with cardiac involvement do very poorly.